Share story
AI

AI shortens drug discovery to around 1 year in China: Insilico CEO

Hong Kong-listed Insilico Medicine has cut drug development timelines to about one year by combining AI with its China research ecosystem, its CEO said. Insilico CEO Alex Zhavoronkov told Reuters in an interview at its Shanghai R&D facility that the company's record is nine months to a developmental candidate, with a typical timeline of 13 months. He said it usually takes about 4.5 years to get to a drug developmental candidate using the traditional approach, but having a research lab in China can cut two years of time.
Sources
emirates247.com
In this story
China
Published by Tech & Business, a media brand covering technology and business. This story was sourced from emirates247.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Policy AI
Policy AI

US orders civilian agencies to remove DeepSeek technology

The United States has ordered federal civilian agencies to stop buying DeepSeek products and services and remove them from government IT systems, according to the Department of Homeland Security. The restrictions also cover third-...

TechCrunch
AI Policy
AI Policy

China establishes centrally administered state-owned data group

China has established a state-owned data group directly administered by the central government, Bloomberg reported. Beijing aims to use the new group to strengthen the country's data infrastructure and support technological develo...

Bloomberg Technology
Capital AI
Capital AI

ASI raises $325 million at $3 billion valuation

ASI has raised $325 million at a $3 billion valuation, Bloomberg reported in an interview with founder and CEO Phillip Buckendorf. The company supplies AI that helps customers including the FAA and military orchestrate complex sys...

Bloomberg Technology